NEW YORK (360Dx) – When researchers at Uppsala University Hospital found a way to make the human neutrophil lipocalin (HNL) biomarker detectable in blood plasma, Philips' executives knew they were on to something interesting.

The research opened the potential to develop a test that could be used at the point of care to rapidly detect bacterial infection, leading to better use of antibiotics, according to Philips.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.